SCHEMBL19980705

SCHEMBL19980705

CCN(CC)C(O)c1cc(F)ccc1-n1cc(C2CCN(C(=O)OC(C)(C)C)CC2)c2ncncc21

nearest known ligand 0.42

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.42
LMNA P02545 3/20 0.40
GPR119 Q8TDV5 7/20 0.40
ALDH1A1 P00352 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
ALOX5AP P20292 1/20 0.37
FEN1 P39748 1/20 0.37
TP53 P04637 1/20 0.37
MAPT P10636 1/20 0.37
THRB P10828 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21084751 0.85 SMN1; SMN2 (0.45) SMN1; SMN2LMNAGPR119ALDH1A1CYP3A4
SCHEMBL30265882 0.85 SMN1; SMN2 (0.45) SMN1; SMN2LMNAGPR119ALDH1A1CYP3A4
SCHEMBL21084750 0.84 SMN1; SMN2 (0.42) SMN1; SMN2LMNAGPR119ALDH1A1CYP3A4
SCHEMBL19972526 0.83 SMN1; SMN2 (0.54) SMN1; SMN2LMNAGPR119ALDH1A1TP53
SCHEMBL31001695 0.83 SMN1; SMN2 (0.54) SMN1; SMN2LMNAGPR119ALDH1A1TP53
SCHEMBL31001708 0.83 SMN1; SMN2 (0.48) SMN1; SMN2LMNAGPR119TP53MAPT
SCHEMBL31001683 0.82 SMN1; SMN2 (0.47) SMN1; SMN2LMNAGPR119ALDH1A1CYP3A4
SCHEMBL19972718 0.82 SMN1; SMN2 (0.47) SMN1; SMN2LMNAGPR119ALDH1A1CYP3A4
SCHEMBL19972506 0.82 SMN1; SMN2 (0.44) SMN1; SMN2LMNAGPR119TP53MAPT
SCHEMBL31001666 0.80 POLB (0.49) SMN1; SMN2LMNAGPR119ALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018053267-A1 INHIBITORS OF THE MENIN-MLL INTERACTION VITAE PHARMACEUTICALS, INC. (US) 2018-03-22 WO disclosed